Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood product specialist remains hopeful that Hemgenix is here to stay. “I hope ...

Despite significant advancements in spinal muscular atrophy (SMA) management, unmet needs persist, especially for patients ...

Belief BioMed (BBM) and Takeda China have announced China’s National Medical Products Administration's (NMPA) approval for ...

Proponents of methods including blood transfusions and gene therapy argue that they can extend longevity. Is it just a delusion?